Mar 22, 2022 7:00am EDT Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 08, 2022 6:30am EST Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Feb 28, 2022 7:00am EST Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022
Jan 18, 2022 7:00am EST Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022
Dec 16, 2021 6:30am EST Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
Nov 18, 2021 7:00am EST Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
Nov 08, 2021 6:35am EST Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
